49 - Decoding minimal residual disease (22 mins)
From Healthier World with Quest Diagnostics · 21:44
Show by Quest Diagnostics
Episode summary Minimal residual disease (MRD) testing is an emerging tool in precision oncology that can provide insights beyond traditional imaging and clinical assessment. In this episode, Rebecca Johnson Wheeler, MS, CGC, and Dr CK Wang explore how circulating tumor DNA (ctDNA) can be used to detect residual disease and discuss how MRD results may help inform recurrence risk, treatment response, and disease surveillance and explore the growing role of MRD testing in cancer care. This episode will Define minimal residual disease and describe how circulating tumor DNA (ctDNA) can be used to detect evidence of cancer that may remain after treatment (4:08) Differentiate tumor-informed and tumor agnostic MRD approaches to testing, and what to consider when selecting an MRD test. (5:57) Explain the clinical significance of MRD results and its clinical utility in muscle invasive bladder cancer care through a case example (9:36) Recognize current and emerging clinical applications of MRD testing (16:00) Date: November 2026 Speaker(s): Rebecca Johnson Wheeler, MS, CGC; CK Wang, MD Contributor(s): Rebecca Johnson Wheeler, MS, CGC; CK Wang, MD; Jared Snider, PhD; Mark Reed, PhD Additional resources: Quest Diagnostics Clinical Education Center Haystack MRD Ordering information: Contact to order Haystack MRD baseline References: National Comprehensive Cancer Network®. Bladder Cancer (Version 3.2026). Published August 2026. Accessed October 2, 2026. https://www.nccn.org Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509-1518. doi:10.1038/s41591-025-03579-w Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA Analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261-2272. doi:10.1056/NEJMoa2200075 Powles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. 2025;393(24):2395-2408. doi:10.1056/NEJMoa2511885 Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022;21(1):86. doi:10.1186/s12943-022-01556-2
More episodes of Healthier World with Quest Diagnostics
More episodes
- 48 - The cardiometabolic-dementia connection (21 min)
- 47 - Beyond BRCA: The bigger picture of hereditary breast cancer (17 mins)
- 46 - New frontiers in PCOS management (23 min)
- 01 - Laboratory assessment in PCOS diagnosis and management (19 min)
- 02 - Laboratory testing for the diagnosis and management of thyroid disorders (21 min)
- 03 - Laboratory assessment in the diagnosis of male Hypogonadism (16 min)
- 04 - Instant insights: Lipoprotein (a) (6 min)
- 05 - Instant insights: Apolipoprotein B (7 min)
- 06 - The insulin resistance revolution: The key to preventing chronic conditions (17 min)
- 07 - Action from insight: Tackling insulin resistance (18 min)
podsearch is a free, independent podcast search engine. Read about podsearch, the privacy policy or contact us.